Congestive heart failure is a common cause of death in Europe and the United States. Depending on the severity of the disease, annual mortality ranges from 10% to 50%.14 The mode of death is circulatory failure or sudden cardiac death, which accounts for approximately 50% of deaths.'-The proportion of sudden death in various studies ranges from 4% to 90%. This variation may be explained partly by different definitions, different patient populations, and the inclusion of non-classifiable deaths in the sudden death category. Non-ischaemic (idiopathic) dilated cardiomyopathy (DCM) is the most common aetiology. In some reports, however, no attempt was made to distinguish between non-ischaemic and ischaemic left ventricular dysfunction because only non-invasive diagnostic procedures were performed. A major shortcoming of some large prospective studies of patients with heart failure is their inclusion of two completely different subgroups (ischaemic and non-ischaemic left ventricular dysfunction). There are many clinical and haemodynamic variables that might predict a poor prognosis owing to impending circulatory failure. It is difficult to identify the patient at risk of sudden death, however, because there are so many different mechanisms and changes in left ventricular function.
Mechanisms of sudden death in DCM Despite the lack of data on the mechanisms of sudden death in patients with DCM, it has been assumed that primary ventricular fibrillation or ventricular tachycardia degenerating into ventricular fibrillation are the most common modes of death (table 1 The presence of ventricular late potentials on the signal averaged electrocardiogram was associated with a poor prognosis in patients with ischaemic heart disease. Several studies that evaluated the use of signal-averaged electrocardiography in the assessment of individuals with diverse underlying clinical diagnosis included a few patients with non-ischaemic DCM. Several small studies suggested that the signal averaged electrocardiogram was useful in the prediction of malignant ventricular tachyarrhythmias in patients with DCM. In patients with coronary artery disease an abnormal signal averaged electrocardiogram successfully identified patients with a high propensity for sustained ventricular tachycardia or even sudden cardiac death. The data were not as conclusive in patients with DCM.
Recently, Mancini et al reported on 114 consecutive patients referred for evaluation for heart transplantation with non-ischaemic DCM.10 They evaluated the usefulness of signal averaged electrocardiography and the impact of bundle branch block QRS morphology on the development of malignant arrhythmic events and all-cause mortality. The best predictor of an adverse outcome defined as death, transplantation, or occurrence of sustained ventricular tachycardia was a higher New York Heart Association classification. The only other predictor of an adverse outcome was an abnormal signal averaged electrocardiogram. These are promising results. However, the clinical application of signal averaged electrocardiography in patients with DCM has the same limitations as those inherent in its use in patients after myocardial infarction. The negative and positive predictive values for predicting sudden death or sustained ventricular tachycardia were 100% and 45%, respectively. Thus when interventions are considered in high risk patients many patients may be treated unnecessarily. None the less, as in post myocardial infarction patients, the prognosis is good if the signal averaged electrocardiogram is normal. Currently, the value of-this non-invasive technique for risk stratification of patients with DCM is presently not known because there have been no prospective, large studies in mildly symptomatic patients.
There are studies of the prognostic value of programmed ventricular stimulation in symptom free patients with DCM.""12 Sustained ventricular tachycardia or fibrillation was inducible in up to 40% of patients (table 2) . These studies showed that the ability of programmed ventricular stimulation to identify those patients with DCM at risk of sudden death was limited because: lation at baseline or poor reproducibility of ventricular tachycardia induction, serial drug testing is not helpful in many patients. Several studies have shown a high recurrence rate for ventricular tachycardia or fibrillation or even sudden death in those patients in whom arrhythmia was not inducible at baseline. '7 19 These findings show that serial drug testing in patients with DCM is useful only in those in whom ventricular tachycardia or fibrillation can reproducibly be induced at baseline when antiarrhythmic drugs are not being giventhat is, for about 50-56% of patients with DCM and a history of sustained ventricular tachycardia or fibrillation. However 20 The actuarial mortality at 1 and 4 years was 0% and 14% for sudden death. Compared with projected mortality these results confirm a significant improvement in prognosis of patients with DCM and life-threatening ventricular tachyarrhythmias and are consistent with similar analyses by other workers in patients with ischaemic heart disease undergoing implantation of a cardioverter-defibrillator.
